Toll Free Helpline (India): 1800 1234 070

Rest of World: +91-9810852116

Free Publication Certificate

Vol. 8, Issue 4 (2019)

Estimation of serum uric acid levels in Parkinson’s disease patients along with their comorbidities and treatment pattern

Author(s):
B Shivani, K Nageswari Devi, V Manasa, Om Prakash Prasad, Anirudda Deshpande, D Sudheer Kumar and P Kishore
Abstract:
To find association of uric acid levels in patients with Parkinson’s disease and its severity. To study the affect of different Comorbid conditions and treatment patterns in Parkinson’s disease patients. A Prospective observational study among 84 patients with Parkinson’s disease was carried out. Serum uric acid levels were determined and association among uric acid levels with disease severity in Parkinson’s disease patients was evaluated using Hoehn and Yahr staging scale. Out of 84 patients, Serum uric acid test was done in 60 patients. Among them 65% were found with uric acid levels less than median value 5.5 mg/dL and 56.6% were found in early stage, 11% were found in advanced stage Parkinson’s disease. In our study, we found inverse association of uric acid levels and its significant correlation with disease severity in early and advanced stage Parkinson’s disease patients. Comorbid condition such as hypertension may be associated with a moderate to severe decline in motor functions. Majority of the patients were treated with Trihexyphenidyl, Carbidopa & Levodopa, Rasagiline. Clinical pharmacist should identify whether the dyskinesia occurred in the patient is drug induced or disease related. This could help physician to provide fractionised dose of Levodopa/Carbidopa for patients and prevent adverse drug reactions.
Pages: 379-385  |  375 Views  72 Downloads


The Pharma Innovation Journal
How to cite this article:
B Shivani, K Nageswari Devi, V Manasa, Om Prakash Prasad, Anirudda Deshpande, D Sudheer Kumar, P Kishore. Estimation of serum uric acid levels in Parkinson’s disease patients along with their comorbidities and treatment pattern. Pharma Innovation 2019;8(4):379-385.

Call for book chapter